科研製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2023/02/27 | 3,630 | 3,665 | 3,630 | 3,665 | +40 | +1.1% | 46,600 |
2023/02/24 | 3,615 | 3,635 | 3,605 | 3,625 | +20 | +0.6% | 42,000 |
2023/02/22 | 3,635 | 3,635 | 3,595 | 3,605 | -30 | -0.8% | 66,300 |
2023/02/21 | 3,625 | 3,640 | 3,620 | 3,635 | -5 | -0.1% | 51,100 |
2023/02/20 | 3,660 | 3,670 | 3,640 | 3,640 | +15 | +0.4% | 52,900 |
2023/02/17 | 3,620 | 3,625 | 3,610 | 3,625 | -10 | -0.3% | 35,600 |
2023/02/16 | 3,640 | 3,660 | 3,630 | 3,635 | -5 | -0.1% | 55,400 |
2023/02/15 | 3,630 | 3,650 | 3,580 | 3,640 | +30 | +0.8% | 101,700 |
2023/02/14 | 3,600 | 3,615 | 3,585 | 3,610 | +30 | +0.8% | 50,100 |
2023/02/13 | 3,605 | 3,615 | 3,575 | 3,580 | -5 | -0.1% | 35,500 |
2023/02/10 | 3,580 | 3,605 | 3,570 | 3,585 | ±0 | ±0% | 52,400 |
2023/02/09 | 3,595 | 3,615 | 3,580 | 3,585 | -30 | -0.8% | 38,300 |
2023/02/08 | 3,600 | 3,635 | 3,600 | 3,615 | +35 | +1% | 53,400 |
2023/02/07 | 3,575 | 3,620 | 3,565 | 3,580 | +35 | +1% | 59,500 |
2023/02/06 | 3,665 | 3,680 | 3,545 | 3,545 | -85 | -2.3% | 142,800 |
2023/02/03 | 3,660 | 3,680 | 3,575 | 3,630 | -60 | -1.6% | 178,300 |
2023/02/02 | 3,715 | 3,735 | 3,690 | 3,690 | -40 | -1.1% | 75,300 |
2023/02/01 | 3,780 | 3,780 | 3,730 | 3,730 | -35 | -0.9% | 35,200 |
2023/01/31 | 3,750 | 3,785 | 3,750 | 3,765 | +10 | +0.3% | 69,700 |
2023/01/30 | 3,755 | 3,765 | 3,735 | 3,755 | -20 | -0.5% | 53,200 |
2023/01/27 | 3,780 | 3,790 | 3,765 | 3,775 | -10 | -0.3% | 32,700 |
2023/01/26 | 3,805 | 3,810 | 3,765 | 3,785 | -30 | -0.8% | 57,600 |
2023/01/25 | 3,810 | 3,835 | 3,780 | 3,815 | -10 | -0.3% | 47,500 |
2023/01/24 | 3,810 | 3,840 | 3,810 | 3,825 | ±0 | ±0% | 39,700 |
2023/01/23 | 3,810 | 3,840 | 3,800 | 3,825 | +50 | +1.3% | 62,100 |
2023/01/20 | 3,780 | 3,790 | 3,760 | 3,775 | +15 | +0.4% | 35,000 |
2023/01/19 | 3,730 | 3,770 | 3,730 | 3,760 | +20 | +0.5% | 51,000 |
2023/01/18 | 3,735 | 3,770 | 3,725 | 3,740 | ±0 | ±0% | 60,400 |
2023/01/17 | 3,745 | 3,760 | 3,720 | 3,740 | +15 | +0.4% | 48,900 |
2023/01/16 | 3,690 | 3,755 | 3,690 | 3,725 | +20 | +0.5% | 46,700 |
2023/01/13 | 3,670 | 3,715 | 3,670 | 3,705 | +30 | +0.8% | 71,500 |
2023/01/12 | 3,685 | 3,685 | 3,655 | 3,675 | +15 | +0.4% | 38,100 |
2023/01/11 | 3,665 | 3,700 | 3,660 | 3,660 | -5 | -0.1% | 45,500 |
2023/01/10 | 3,710 | 3,725 | 3,665 | 3,665 | -10 | -0.3% | 69,500 |
2023/01/06 | 3,730 | 3,730 | 3,660 | 3,675 | -20 | -0.5% | 64,900 |
2023/01/05 | 3,750 | 3,760 | 3,695 | 3,695 | -85 | -2.2% | 82,400 |
2023/01/04 | 3,850 | 3,855 | 3,775 | 3,780 | -110 | -2.8% | 55,700 |
2022/12/30 | 3,925 | 3,930 | 3,890 | 3,890 | -25 | -0.6% | 32,200 |
2022/12/29 | 3,890 | 3,915 | 3,855 | 3,915 | +10 | +0.3% | 38,400 |
2022/12/28 | 3,895 | 3,920 | 3,880 | 3,905 | +15 | +0.4% | 43,500 |
2022/12/27 | 3,875 | 3,920 | 3,875 | 3,890 | +15 | +0.4% | 31,700 |
2022/12/26 | 3,890 | 3,890 | 3,865 | 3,875 | -15 | -0.4% | 24,000 |
2022/12/23 | 3,890 | 3,895 | 3,865 | 3,890 | ±0 | ±0% | 34,400 |
2022/12/22 | 3,860 | 3,895 | 3,820 | 3,890 | +35 | +0.9% | 44,600 |
2022/12/21 | 3,880 | 3,900 | 3,840 | 3,855 | -30 | -0.8% | 62,700 |
2022/12/20 | 3,890 | 3,915 | 3,840 | 3,885 | -25 | -0.6% | 91,700 |
2022/12/19 | 3,885 | 3,920 | 3,860 | 3,910 | +20 | +0.5% | 47,900 |
2022/12/16 | 3,900 | 3,925 | 3,880 | 3,890 | -25 | -0.6% | 78,200 |
2022/12/15 | 3,910 | 3,935 | 3,905 | 3,915 | ±0 | ±0% | 40,800 |
2022/12/14 | 3,930 | 3,945 | 3,900 | 3,915 | -10 | -0.3% | 39,700 |
301~
350
件表示中 / 3458件
類似銘柄と比較する
現在ご覧いただいている「科研薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
科研薬 | 344,000円 | +4.2% | -21.6% | 4.36% | 23.26倍 | 0.91倍 |
|
旧理研グループの名門。導入の関節機能改善剤、自社創製の爪白癬症薬の2本柱。後発品も展開 |
日本新薬 | 369,300円 | +1.2% | -6.3% | 3.36% | 10.15倍 | 1.13倍 |
|
医家向け医薬品主体、自社創薬は泌尿器科、血液内科、難病・希少疾患に集中。機能食品も育成 |
ペプチド | 191,500円 | +56.7% | +357.2% | 0.00% | 17.73倍 | 6.15倍 |
|
東大発のペプチド創薬ベンチャーの雄。海外製薬大手との提携多数。買収で放射性医薬品に参入 |
キッセイ薬 | 316,000円 | +9.8% | -12.1% | 2.85% | 12.36倍 | 0.63倍 |
|
医薬品中堅。泌尿器、腎・透析、未充足医療が重点領域。主軸特許切れ、新しい柱育成。海外は導出 |
東和薬品 | 273,000円 | +14.7% | -28.1% | 2.20% | 11.58倍 | 0.86倍 |
|
後発医薬品メーカーで国内2強の一角。循環器系に強い。直販軸に発展も卸との取引を拡大中 |
市場注目の銘柄
チャート関連のコラム